Previous close | 2.3600 |
Open | 3.3800 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 17.00 |
Expiry date | 2023-01-20 |
Day's range | 2.3600 - 3.3800 |
Contract range | N/A |
Volume | |
Open interest | 1.36k |
OSAKA, Japan & CAMBRIDGE, Mass., June 30, 2022--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently no lo
OSAKA, Japan & PASADENA, Calif., June 27, 2022--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.
CAMBRIDGE, Mass., June 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology